This Article Full Text (PDF) Other Versions of this Article: JVI.01691-07v1 82/2/638    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, Y. Articles by Hu, S.-L. Search for Related Content PubMed PubMed Citation Articles by Li, Y. Articles by Hu, S.-L.

 Previous Article  |  Next Article 

J. Virol. doi:10.1128/JVI.01691-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Removal of a single N-linked glycan in HIV-1 gp120 results in enhanced ability to induce neutralizing antibody responses

Department of Pharmaceutics, Washington National Primate Research Center and Department of Biostatistics, University of Washington, Seattle, WA, USA; Duke University Medical Center, Durham, NC, USA

^* To whom correspondence should be addressed. Email: hus{at}u.washington.edu.

	Abstract

Glycans on HIV envelope protein play an important role in infection and evasion from host immune responses. To examine the role of specific glycans, we introduced single or multiple mutations into potential N-linked glycosylation sites in hypervariable regions (V1-V3) of the env gene of HIV-1 89.6. Three mutants tested showed enhanced sensitivity to soluble CD4. Mutant N7 (N197Q) in the carboxy-terminal stem of the V2 loop showed the most pronounced increase in sensitivity to broadly neutralizing antibodies (NtAb), including those targeting the CD4-binding site (IgG1b12) and the V3 loop (447-52D). This mutant is also sensitive to CD4-induced NtAb17b in the absence of CD4. Unlike wild-type (WT) Env, mutant N7 mediates CD4-independent infection in U87-CXCR4 cells. To study the immunogenicity of mutant Env, we immunized pig-tailed macaques with recombinant vaccinia viruses, one expressing SIVmac239 Gag-Pol, and the other, HIV-1 89.6 Env gp160 in WT or mutant forms. Animals were boosted 14-16 months later with SIV gag DNA and the cognate gp140 protein before intrarectal challenge with SHIV89.6P-MN. Day-of-challenge sera from animals immunized with mutant N7 Env had significantly higher and broader neutralizing activities than sera from WT Env-immunized animals. Neutralizing activity was observed against SHIV89.6, SHIV89.6P-MN, HIV-1 SF162, and a panel of subtype B primary isolates. Compared to control animals, immunized animals showed significant reduction of plasma viral load and increased survival after challenge, which correlated with prechallenge NtAb titers. These results indicate the potential advantages for glycan modification in vaccine design, although the role of specific glycans requires further examination.

This article has been cited by other articles:

• Chen, H., Xu, X., Lin, H.-H., Chen, S.-H., Forsman, A., Aasa-Chapman, M., Jones, I. M. (2008). Mapping the immune response to the outer domain of a human immunodeficiency virus-1 clade C gp120. J. Gen. Virol. 89: 2597-2604 [Abstract] [Full Text]  
• Luallen, R. J., Lin, J., Fu, H., Cai, K. K., Agrawal, C., Mboudjeka, I., Lee, F.-H., Montefiori, D., Smith, D. F., Doms, R. W., Geng, Y. (2008). An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies. J. Virol. 82: 6447-6457 [Abstract] [Full Text]